产品
编 号：F447776
分子式：C12H7ClO2S2
分子量：282.77
分子式：C12H7ClO2S2
分子量：282.77
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 748778-73-6
产品详情
生物活性：
YC-001 is an inverse agonist and antagonist of rod opsin. YC-001 reversibly binds rod opsin and stabilizes the rod opsin structure. YC-001 protects mice from bright light-induced retinal degeneration. YC-001 has the potential for the research of retinal degeneration.
体内研究：
YC-001 (50, 200mg/kg; i.p.) protects Abca4?/?Rdh8?/? mice from bright light-induced retinal degeneration.YC-001 (200mg/kg; i.p.) enters mouse eyes after systemic administration but is not retained for prolonged periods.YC-001 (100 mg/kg, 200 mg/kg; i.p.; daily for 24 days) shows virtually no acute toxicity.Animal Model:6-week-old Abca4 ?/?Rdh8?/? mice
Dosage:50, 200mg/kg
Administration:I.P.
Result:Protected Abca4?/?Rdh8?/? mice from bright light-induced retinal degeneration.
Animal Model:C57BL/6 mouse
Dosage:200 mg/kg
Administration:I.P.
Result:Entered mouse eyes after systemic administration but is not retained for prolonged periods.
Animal Model:C57BL/6 mice
Dosage:100 mg/kg, 200 mg/kg
Administration:I.p.; daily, 24 days
Result:Showed no acute toxicity.
体外研究：
YC-001 (0-100 μM) shows a potency activity of 8.7 μM and an efficacy at 150–310%.YC-001 (0.5, 1, 5, 10, 20, 40 μM) improves the glycosylation profile of P23H opsin mutant.YC-001 (0,-1.5 μM) reversibly binds rod opsin with EC50 OF 0.98 μM.YC-001 (0.313, 0.625, 1.25, 2.5, 5, 10, 20, 80 μM) increases in cAMP level in a dose-dependent manner in NIH3T3 cells.
YC-001 is an inverse agonist and antagonist of rod opsin. YC-001 reversibly binds rod opsin and stabilizes the rod opsin structure. YC-001 protects mice from bright light-induced retinal degeneration. YC-001 has the potential for the research of retinal degeneration.
体内研究：
YC-001 (50, 200mg/kg; i.p.) protects Abca4?/?Rdh8?/? mice from bright light-induced retinal degeneration.YC-001 (200mg/kg; i.p.) enters mouse eyes after systemic administration but is not retained for prolonged periods.YC-001 (100 mg/kg, 200 mg/kg; i.p.; daily for 24 days) shows virtually no acute toxicity.Animal Model:6-week-old Abca4 ?/?Rdh8?/? mice
Dosage:50, 200mg/kg
Administration:I.P.
Result:Protected Abca4?/?Rdh8?/? mice from bright light-induced retinal degeneration.
Animal Model:C57BL/6 mouse
Dosage:200 mg/kg
Administration:I.P.
Result:Entered mouse eyes after systemic administration but is not retained for prolonged periods.
Animal Model:C57BL/6 mice
Dosage:100 mg/kg, 200 mg/kg
Administration:I.p.; daily, 24 days
Result:Showed no acute toxicity.
体外研究：
YC-001 (0-100 μM) shows a potency activity of 8.7 μM and an efficacy at 150–310%.YC-001 (0.5, 1, 5, 10, 20, 40 μM) improves the glycosylation profile of P23H opsin mutant.YC-001 (0,-1.5 μM) reversibly binds rod opsin with EC50 OF 0.98 μM.YC-001 (0.313, 0.625, 1.25, 2.5, 5, 10, 20, 80 μM) increases in cAMP level in a dose-dependent manner in NIH3T3 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备